NOXXON Pharma AG


NOXXON Pharma is a biotechnology company whose core focus is on cancer treatment. NOXXON is using its proprietary class of drugs called Spiegelmers* to target the tumor microenvironment, a new frontier in cancer treatment. NOXXON's goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. NOXXON's Spiegelmer platform has generated a broad proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12 and additional candidates outside oncology: Pipeline

NOXXON Pharma is a biotechnology company whose core focus is on cancer treatment. NOXXON is using its proprietary class of drugs called Spiegelmers* to target the tumor microenvironment, a new frontier in cancer treatment. NOXXON's goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy.

NOXXON's Spiegelmer platform has generated a broad proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12 and additional candidates outside oncology: Pipeline